PGEN

Precigen (PGEN) has dosed the first patients with PRGN-3005 UltraCAR-T cells in the intraperitoneal arm of the ongoing Phase 1 study for advanced ovarian cancer patients, and with PRGN-3006 UltraCAR-T cells in

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical implementation of its UltraPorator™ system, a device exclusive to Precigen for the scale-up of rapid and cost-effective decentralized manufacturing of UltraCAR-T® therapies. Precigen and its clinical partners have now successfully dosed the first patients with UltraCAR-T cells manufactured using the UltraPorator system. The patients were dosed with PRGN-3005 UltraCAR-T cells in the intraperitoneal (IP) arm of the ongoing Phase 1 study for advanced ovarian cancer patients conducted in collaboration with the University of Washington/Fred Hutchinson Cancer Research Center and with PRGN-3006 UltraCAR-T cells in the ongoing Phase 1/1b study for patients with relapsed or refractory acute myeloid leukemia (AML) and higher risk myelodysplastic syndrome (MDS) conducted in collaboration with the Moffitt Cancer Center. UltraCAR-T eliminates ex vivo expansion, which reduces manufacturing time to allow for rapid next day administration of UltraCAR-T cells following non-viral gene transfer.

Precigen (PGEN): Q3 GAAP EPS of -$0.18 misses by $0.04.Revenue of $23.58M (+28.9% Y/Y) beats by $5.88M."The Precigen team has made impressive progress this quarter in driving value across our

Precigen (NASDAQ:PGEN) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 47.06 percent increase over losses of $(0.34) per share from the

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today named Gaurav Vij as the Company's head of business development. Mr. Vij will have responsibility for accelerating strategic business development activities across Precigen's platform and pipeline programs, including identifying and building new strategic partnerships to rapidly progress core assets. Mr. Vij will report to Precigen's President and CEO, Helen Sabzevari, PhD, and will join Precigen's leadership team. This position adds to the ongoing evolution of Precigen's leadership team and supports the Company's continued focus on healthcare and strategic partnering of our innovative preclinical and clinical portfolio.

Gainers: Staffing 360 Solutions (STAF) +86%.China HGS Real Estate (HGSH) +65%.Huttig Building Products (HBP) +39%.Dragon Victory International (LYL) +35%.SPI Energy (SPI) +30%.Organogenesis (ORGO) +20%.Armata Pharmaceuticals (ARMP) +20%.Cars.com (CARS) +18%.Precigen (PGEN) +17%.GameStop (GME) +16%.Losers: Kaixin Auto

Gainers: Organogenesis Holdings (ORGO) +22%, Anavex Life Sciences (AVXL) +16%, Precigen (PGEN) +12%, Replimune Group (REPL) +11%, Armata Pharmaceuticals (ARMP) +11%.Losers: Vertex Pharmaceuticals (VRTX) -20%, Aphria (APHA) -16%, Cyclerion Therapeutics (CYCN) -13%, Liquidia Technologies (LQDA) -9%, Arvinas (ARVN) -7%.